138 related articles for article (PubMed ID: 6968751)
21. Designing synthetic superagonists of C3a anaphylatoxin.
Ember JA; Johansen NL; Hugli TE
Biochemistry; 1991 Apr; 30(15):3603-12. PubMed ID: 2015217
[TBL] [Abstract][Full Text] [Related]
22. Factor C3f is a spasmogenic fragment released from C3b by factors I and H: the heptadeca-peptide C3f was synthesized and characterized.
Ganu VS; Müller-Eberhard HJ; Hugli TE
Mol Immunol; 1989 Oct; 26(10):939-48. PubMed ID: 2531841
[TBL] [Abstract][Full Text] [Related]
23. Studies on the ileum-contracting mechanisms and identification as a complement C3a receptor agonist of oryzatensin, a bioactive peptide derived from rice albumin.
Takahashi M; Moriguchi S; Ikeno M; Kono S; Ohata K; Usui H; Kurahashi K; Sasaki R; Yoshikawa M
Peptides; 1996; 17(1):5-12. PubMed ID: 8822503
[TBL] [Abstract][Full Text] [Related]
24. Microvascular effects of anaphylatoxins C3a and C5a.
Björk J; Hugli TE; Smedegård G
J Immunol; 1985 Feb; 134(2):1115-9. PubMed ID: 3871207
[TBL] [Abstract][Full Text] [Related]
25. Partial characterization of human C5a anaphylatoxin. I. Chemical description of the carbohydrate and polypeptide prtions of human C5a.
Fernandez HN; Hugli TE
J Immunol; 1976 Nov; 117(5 Pt 1):1688-94. PubMed ID: 1002996
[TBL] [Abstract][Full Text] [Related]
26. Comparative study on biological activities of various anaphylatoxins (C4a, C3a, C5a). Investigations on their ability to induce platelet secretion.
Meuer S; Hugli TE; Andreatta RH; Hadding U; Bitter-Suermann D
Inflammation; 1981 Dec; 5(4):263-73. PubMed ID: 6976935
[TBL] [Abstract][Full Text] [Related]
27. Anaphylatoxin C3a peptide contracts human pulmonary vasculature.
Schellenberg RR; Mullen JB; Foster A; Glovsky MM
Pulm Pharmacol; 1988; 1(3):133-8. PubMed ID: 2980296
[TBL] [Abstract][Full Text] [Related]
28. Amino acid sequence of guinea pig C3a anaphylatoxin.
Gerard NP; Lively MO; Gerard C
Protein Seq Data Anal; 1988; 1(6):473-8. PubMed ID: 3064079
[TBL] [Abstract][Full Text] [Related]
29. Anaphylatoxin-induced neutrophil chemotaxis and aggregation. Limited aggregation and specific desensitization induced by human C3a and synthetic C3a octapeptides.
Nagata S; Glovsky MM; Kunkel SL
Int Arch Allergy Appl Immunol; 1987; 82(1):4-9. PubMed ID: 3492446
[TBL] [Abstract][Full Text] [Related]
30. Biochemistry and biology of anaphylatoxins.
Hugli TE
Complement; 1986; 3(3):111-27. PubMed ID: 3542363
[TBL] [Abstract][Full Text] [Related]
31. A synthetic nonapeptide corresponding to the NH2-terminal sequence of C3d-K causes leukocytosis in rabbits.
Hoeprich PD; Dahinden CA; Lachmann PJ; Davis AE; Hugli TE
J Biol Chem; 1985 Mar; 260(5):2597-600. PubMed ID: 3871772
[TBL] [Abstract][Full Text] [Related]
32. Evidence for a role of the amino-terminal region in the biological activity of the classical anaphylatoxin, porcine C5a des-Arg-74.
Gerard C; Showell HJ; Hoeprich PD; Hugli TE; Stimler NP
J Biol Chem; 1985 Mar; 260(5):2613-6. PubMed ID: 3972798
[TBL] [Abstract][Full Text] [Related]
33. Human anaphylatoxin (C3a) from the third component of complement. Primary structure.
Hugli TE
J Biol Chem; 1975 Nov; 250(21):8293-301. PubMed ID: 1238393
[TBL] [Abstract][Full Text] [Related]
34. Effect of C3a and C5a anaphylatoxins on guinea-pig isolated blood vessels.
Marceau F; Hugli TE
J Pharmacol Exp Ther; 1984 Sep; 230(3):749-54. PubMed ID: 6332191
[TBL] [Abstract][Full Text] [Related]
35. Peptide analogues of the anaphylatoxin C3a; syntheses and properties.
Ambrosius D; Casaretto M; Gerardy-Schahn R; Saunders D; Brandenburg D; Zahn H
Biol Chem Hoppe Seyler; 1989 Mar; 370(3):217-27. PubMed ID: 2713103
[TBL] [Abstract][Full Text] [Related]
36. Functional activities of synthetic anaphylatoxic peptides in widely used biological assays.
Kola A; Klos A; Bautsch W; Kretzschmar T; Köhl J
Clin Exp Immunol; 1992 May; 88(2):368-72. PubMed ID: 1572104
[TBL] [Abstract][Full Text] [Related]
37. Characterization of synthetic C3a analog peptides on human eosinophils in comparison to the native complement component C3a.
Petering H; Köhl J; Weyergraf A; Dulkys Y; Kimmig D; Smolarski R; Kapp A; Elsner J
J Immunol; 2000 Apr; 164(7):3783-9. PubMed ID: 10725738
[TBL] [Abstract][Full Text] [Related]
38. Cardiac dysfunction caused by purified human C3a anaphylatoxin.
del Balzo UH; Levi R; Polley MJ
Proc Natl Acad Sci U S A; 1985 Feb; 82(3):886-90. PubMed ID: 2579381
[TBL] [Abstract][Full Text] [Related]
39. Mast cells are not required for anaphylatoxin-induced ileal smooth muscle contraction.
Stimler-Gerard NP; Galli SJ
J Immunol; 1987 Mar; 138(6):1908-13. PubMed ID: 2434565
[TBL] [Abstract][Full Text] [Related]
40. Role of the amino- and carboxyl-terminal domains of thrombin receptor-derived polypeptides in biological activity in vascular endothelium and gastric smooth muscle: evidence for receptor subtypes.
Hollenberg MD; Laniyonu AA; Saifeddine M; Moore GJ
Mol Pharmacol; 1993 Jun; 43(6):921-30. PubMed ID: 8391118
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
